title: Fibrotic valvular heart disease subsequent to bromocriptine treatment.
abstract: Ergot alkaloids, such as ergotamine, have been associated with numerous vascular complications and with valvular heart disease. The authors describe a man who developed fibrosis of three heart valves during a 5-year treatment with bromocriptine for Parkinson disease. There were no other plausible causes. To our knowledge, such a side effect has never been described with this drug.
authors.affiliation: Service de Médecine Interne, the Service de Cardiologie B, CHU Timone, Marseille Cedex 5, France.
authors.forename: Jacques
authors.initials: J
authors.lastname: Serratrice
authors.forename: Patrick
authors.initials: P
authors.lastname: Disdier
authors.forename: Gilbert
authors.initials: G
authors.lastname: Habib
authors.forename: François
authors.initials: F
authors.lastname: Viallet
authors.forename: Pierre-Jean
authors.initials: PJ
authors.lastname: Weiller
mesh_terms: D001971:Bromocriptine / Q000009:adverse effects* / Q000627:therapeutic use; D005355:Fibrosis / Q000139:chemically induced* / Q000175:diagnosis; D006349:Heart Valve Diseases / Q000139:chemically induced* / Q000175:diagnosis; D006801:Humans; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy
chemical_list: D001971:Bromocriptine